Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer
NCT02501603
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
72
Enrollment
OTHER
Sponsor class
Conditions
Gastric Cancer
Gastroesophageal Junction Cancer
Interventions
DRUG:
afatinib
DRUG:
paclitaxel
Sponsor
Yonsei University